A new study conducted by NeOnc into the efficacy of its NEO 100 formulation to safely deliver therapeutics to the brain through the Blood-Brain Barrier was concluded in August 2020. This study was done to specifically study not only the ability to permeate the BBB but also the impact such migration would have on the […]
NeOnc Technologies Holdings conducted a study of its NEO100 Perillyl Alcohol (POH) formulation to determine its in vitro Blood-Brain Barrier (BBB) permeability using transepithelial/transendothelial electrical resistance (TEER) and antibody diffusion assays. Ultrasound-guided intracardiac administration of NEO100, followed by intravenous application of Evan’s blue, methotrexate, checkpoint-inhibitory antibodies, or CAR T-cells was conducted on mouse models. The […]
A new study into the effectiveness of NEO212, a conjugate formulation of Temozolomide (TMZ) and Perillyl Alcohol (POH) designed for intranasal delivery, to enhance the ability of (TMZ) to slow or stop the formation of Glioblastoma Tumors suggests additional benefits over TMZ treatment alone. For those with Glioblastoma (GB) brain cancer, the survival prognosis is […]
A study showed that intranasal delivery with a NEO100-based formulation enables noninvasive, therapeutic delivery to the brain of a pharmaceutical agent that otherwise does not efficiently cross the BBB. One such agent is bortezomib (BZM), a proteasome inhibitor that is approved for the treatment of multiple myeloma. Preclinical studies established that BZM can be effective […]
Many pharmaceutical agents are highly potent but are unable to exert therapeutic activity against disorders of the central nervous system {CNS) because the blood-brain barrier (BBB) impedes their brain entry. Preclinical studies established that Bortezomib (BZM), a proteasome inhibitor that is approved for the treatment of multiple myeloma, can be effective against glioblastoma {GBM), but […]
Glioblastoma (GBM) is a highly aggressive primary brain tumor with a poor prognosis. Treatment with temozolomide, the current standard of care for gliomas, usually results in drug resistance and tumor recurrence. Therefore, there is a great need for drugs that target GBM. In response to this, NeOnc Technologies Holdings, Inc. created NEO214 by covalently linking […]
The use of intranasal NEO100 as an agent to treat a neurological disease such as GBM is unique in that it suggests the feasibility of nasal brain delivery via the cranial nerves, thereby avoiding the obstacle presented by the BBB. This delivery method also reduces exposure through the systemic circulation, by that minimizing the systemic […]
NeOnc Technologies Holdings conducted a study to examine the effects of its NEO212 formulation in helping to block one of the key processes in cancer tumor growth. In tumor cells, the endothelial-to-mesenchymal transition (EndMT) supports the pro-angiogenic and invasive characteristics of glioblastoma multiforme (GBM). Blocking this process would be a promising approach to inhibit tumor […]
Glioblastoma multiforme (GBM) is a malignant brain tumor characterized by its extensive vascularity, aggressiveness, and invasiveness, where cell migration plays an important role in tumor progression. Its poor prognosis is associated with high recurrence, and resistance to the current standard of care chemotherapy, temozolomide (TMZ). Despite great progress made in surgery and therapies, there has […]
Despite the introduction of new therapies for multiple myeloma (MM), many patients are still dying from this disease and novel treatments are urgently needed. NeOnc Technologies Holdings, Inc. designed a novel hybrid molecule, called NEO214, that was generated by covalent conjugation of the natural monoterpene perillyl alcohol (POH), an inducer of endoplasmic reticulum (ER) stress, […]
